

DIAXONHIT – Transplantation tests

Renewal of commercial partnership with One Lambda, Inc. for diagnostic tests in transplantation

- With this exclusive partnership, DIAXONHIT's InGen confirms its commitment in France for diagnostic tests in transplantation

Paris, France – November 12, 2014 - DIAXONHIT (Alternext : ALEHT, FR0004054427), a French leader in specialty in-vitro diagnostics for transplantation, infectious diseases and cancer, announces on behalf of its affiliate, InGen, the renewal of the exclusive commercial partnership for the commercialization in France of diagnostic tests for transplantation developed by One Lambda, Inc.

Today, DIAXONHIT's InGen is the largest provider of diagnostic products to laboratories that are responsible for carrying out all tests related to transplantation in France. With a strong position in this sector, InGen has grown its total sales by 11% in the field of transplantation during 2013 .

"The renewal of this exclusive partnership demonstrates the quality of our sales team and the confidence of One Lambda in our marketing abilities. It enables our Group to strengthen its investment strategy over the long term in all areas of transplantation in order to further develop this critical market" says Dr. Loïc Maurel, President of the Management Board of Diaxonhit.

One Lambda develops and distributes several lines of HLA¹ typing tests utilizing both serological and molecular technologies. It manufactures a comprehensive line of antibody detection products that have been designed to monitor transplant patients, both pre- and post-transplant. They are used to detect HLA antibodies that may cause graft rejection. One Lambda also manufactures laboratory instrumentation, and computer software that are used to simplify and automate testing procedures and final test evaluations. With five different product lines, One Lambda allows laboratories to choose a solution that best suits their needs.

HLA tests marketed by DIAXONHIT's InGen are used to assess the compatibility between donor and recipient before transplantation, and to follow-up transplanted patients in order to monitor potential rejection and adjust immunosuppressive treatments accordingly. Before transplantation, HLA typing is performed routinely by serology or molecular biology, as well as detection of anti-HLA antibodies synonymous with increased risk of rejection. After transplantation, rejection is monitored with tests that identify anti-HLA antibodies present in patients. All these tests are performed in the HLA laboratories of the French Blood Bank, and in histocompatibility (immunology) laboratories of university hospitals.

The field of transplantation covers all activities related to organ and bone marrow transplants. In 2013, 5,123 transplants were performed in France, up 45% since 2000⁽²⁾ with rejection remaining the main risk. The rates of acute rejection within a year after transplantation ranging from 5% (kidney) to 50% (lung)⁽²⁾, the need for reliable diagnostic tests is essential.

¹ Human Leucocyte Antigen

² Source : Inserm, www.inserm.fr/thematiques/sante-publique/dossiers-d-information/transplantation-d-organes

About One Lambda, Inc.

One Lambda is the worldwide leader in HLA typing and antibody detection assays. One Lambda is known for its commitment to quality, service, and innovation. The company develops and distributes several lines of HLA typing and antibody detection tests utilizing serological, molecular, ELISA, flow cytometry, and Luminex™ xMAP™ technologies. In addition, One Lambda also manufactures laboratory instrumentation and computer software that are used to simplify and automate testing procedures and final test evaluations.

For more information, please visit <http://www.onelambda.com>

About DIAXONHIT

Diaxonhit (NYSE Alternext, FR0004054427, ALEHT) is a French fully integrated leader in *in vitro* diagnostics, involved from research to commercialization of specialty diagnostic products in the fields of transplantation, infectious diseases and cancer. With many partnerships and a strong presence in hospitals, Diaxonhit has an extensive commercialization network. Through its affiliate, InGen, it commercializes and services, mostly under exclusivity agreements, *in-vitro* diagnostic kits and advanced equipment, quality control products and rapid tests, including Tetanus Quick Stick®, a proprietary product. InGen is the leading supplier in France of HLA tests manufactured by One Lambda. The group also owns a diversified portfolio of products in development, including both innovative molecular and non-molecular diagnostics, covering its three main specialty areas: transplantation, immuno-infection and cancer. Diaxonhit headquarters are located in Paris and its affiliate in the Paris region. The Group is listed on NYSE Alternext in Paris and is part of both the NYSE Alternext OSEO Innovation and the Next Biotech indices.

For more information, please visit: <http://www.diaxonhit.com>

Symbol : ALEHT - ISIN Code: FR0004054427 - Reuters : ALEHT.PA - Bloomberg : ALEHT:FP

Contacts

DIAXONHIT

Hervé Duchesne de Lamotte, CFO, +33 (0)1 53 94 52 49, herve.delamotte@diaxonhit.com

NewCap

Julien Perez, Investors Relations & Financial Communication, +33 (0)1 44 71 98 52, jperez@newcap.fr
Annie-Florence Loyer, Media Relations, +33 (0)1 44 71 98 50, afloyer@newcap.fr

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements about future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated. In addition, Diaxonhit, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only. Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the English language version shall prevail.

